Acceder

Publicaciones - HEMATOLOGÍA Y ONCOLOGÍA MÉDICA CLÍNICO-EXPERIMENTAL

Cargando...
Gordon J, Bravo-Perez C, Guarnera L, Unlu S, Kawashima N, Ahmed A, Haddad C, Kubota Y, Nautiyal I, Ullah F, Dima D, Williams ND, Kewan T, Bahaj W, Carraway HE, Yang CY, Gurnari C, Visconte V, Maciejewski JP. Non-canonical FLT3 alterations reveal novel germline FLT3 variants leading to somatic gene rescue mutations. Blood Cancer J. 2024 Jul 30;14(1):125. doi: 10.1038/s41408-024-01104-9. No abstract available. PubMed PMID: 39080258; PubMed Central PMCID: PMC11289469.
AÑO: 2024; IF: 11.6
39080258
Rivera F, Longo F, Martin Richard M, Richart P, Alsina M, Carmona A, Custodio AB, Fernandez Montes A, Gallego J, Fleitas Kanonnikoff T. SEOM-GEMCAD-TTD clinical guideline for the diagnosis and treatment of gastric cancer (2023). Clin Transl Oncol. 2024 Nov;26(11):2826-2840. doi: 10.1007/s12094-024-03600-7. Epub 2024 Jul 18. PubMed PMID: 39023829; PubMed Central PMCID: PMC11467061.
AÑO: 2024; IF: 2.5
39023829
Garrote M, Lopez-Guerra M, Garcia-Pagan JC, Arellano-Rodrigo E, Ferrer-Marin F, Hernandez-Boluda JC, Bellosillo B, Nomdedeu M, Hernandez-Gea V, Triguero A, Guijarro F, Alamo J, Baiges A, Turon F, Colomer D, Cervantes F, Alvarez-Larran A. Genomic classification and outcomes of young patients with polycythemia vera and essential thrombocythemia according to the presence of splanchnic vein thrombosis and its chronology. Ann Hematol. 2024 Mar;103(3):737-747. doi: 10.1007/s00277-023-05610-x. Epub 2024 Jan 24. PubMed PMID: 38263537; PubMed Central PMCID: PMC10866782.
AÑO: 2024; IF: 2.4
38263537
Kiladjian JJ, Marin FF, Al-Ali HK, Alvarez-Larran A, Beggiato E, Bieniaszewska M, Breccia M, Buxhofer-Ausch V, Cerna O, Crisan AM, Danaila CD, De Stefano V, Dohner K, Empson V, Gora-Tybor J, Griesshammer M, Grosicki S, Guglielmelli P, Garcia-Gutierrez V, Heidel FH, Illes A, Tomuleasa C, James C, Koschmieder S, Krauth MT, Krejcy K, Lazaroiu MC, Mayer J, Nagy ZG, Nicolini FE, Palandri F, Pappa V, Reiter AJ, Sacha T, Schlager S, Schmidt S, Terpos E, Unger M, Wolfler A, Cirici BX, Klade C. ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options. Ann Hematol. 2024 Jul;103(7):2299-2310. doi: 10.1007/s00277-024-05665-4. Epub 2024 Mar 4. PubMed PMID: 38438627; PubMed Central PMCID: PMC11224110.
AÑO: 2024; IF: 2.4
38438627
Arrizabalaga L, Garcia-Torralba E, Galluzzi L, Buque A. Targeting CDK2 to circumvent treatment resistance in HR+ breast cancer. Trends Mol Med. 2024 Dec 27:S1471-4914(24)00342-3. doi: 10.1016/j.molmed.2024.12.009. Online ahead of print. PubMed PMID: 39732571.
AÑO: 2024; IF: 13.8
39732571
< AnteriorSiguiente >
IMIB-Arrixaca

Instituto de Investigación Sanitaria Acreditado

ISCII

HEMATOLOGÍA Y ONCOLOGÍA MÉDICA CLÍNICO-EXPERIMENTAL